Consumption of Cuban Policosanol Improves Blood Pressure and Lipid Profile via Enhancement of HDL Functionality in Healthy Women Subjects: Randomized, Double-Blinded, and Placebo-Controlled Study
Table 1
Change of blood pressure and plasma profile after 8 weeks consumption.
Placebo ()
Policosanol ()
Age
31 ± 16
31 ± 15
Week 0
Week 8
Week 0
Week 8
Body composition
BMI
21 ± 3
21 ± 3
21 ± 4
21 ± 4
Total body fat (kg)
13.5 ± 3
13.1 ± 3
15.2 ± 4
13.8 ± 4
Percentage of body fat (%)
24 ± 5
23 ± 6
25 ± 6
23 ± 5
Subcutaneous fat (kg)
11.9 ± 2.1
11.7 ± 2.4
13.6 ± 3.3
12.5 ± 3.0
Visceral fat (kg)
1.3 ± 0.4
1.4 ± 0.4
1.5 ± 0.5
1.2 ± 0.4
Blood pressure (mmHg)
SphygmoCor XCEL
Systolic
133 ± 14
126 ± 8
131 ± 10
118 ± 14
Diastolic
87 ± 10
85 ± 8
82 ± 9
75 ± 7
Omron blood pressure monitor
Systolic
131 ± 16
129 ± 9
130 ± 10
119 ± 8
Diastolic
86 ± 11
85 ± 7
83 ± 8
67 ± 7
Mercury sphygmomanometer
Systolic
131 ± 9
125 ± 8
129 ± 8
116 ± 12
Diastolic
84 ± 6
83 ± 5
84 ± 8
72 ± 8
Average blood pressure
Systolic
132 ± 12
127 ± 7
130 ± 7
117 ± 14
Diastolic
86 ± 9
84 ± 6
83 ± 8
72 ± 8
Augmentation index (AI)
17 ± 3
16 ± 3
16 ± 3
7 ± 1
Augmentation pressure (AP)
7 ± 1
5 ± 1
7 ± 2
2 ± 0
Plasma profile
TC (mg/dL)
195 ± 22
201 ± 21
180 ± 14
146 ± 10
TG (mg/dL)
84 ± 17
92 ± 20
83 ± 16
72 ± 12
HDL-C (mg/dL)
42 ± 3
45 ± 4
42 ± 4
53 ± 8
%HDL-C
21 ± 3
22 ± 3
23 ± 2
36 ± 4
TG/HDL-C
2.0 ± 0.6
2.1 ± 0.6
2.0 ± 0.2
1.4 ± 0.1
Calculated LDL-C (mg/dL)
138 ± 22
137 ± 20
125 ± 11
81 ± 7
Glucose (mg/dL)
87 ± 5
89 ± 5
91 ± 6
83 ± 5
CETP activity (% CE transfer)
38 ± 4
40 ± 4
39 ± 5
31 ± 4
CETP amount (μg/mL)
1.9 ± 0.2
1.9 ± 0.2
2.0 ± 0.2
1.5 ± 0.1
Uric acid (mg/dL)
6.7 ± 1.4
6.5 ± 2.4
6.6 ± 0.8
5.3 ± 1.2
Aldosterone (ng/dL)
19 ± 7
25 ± 8
38 ± 10
23 ± 6
AU: arbitrary unit; BP: blood pressure; BMI: body mass index; CETP: cholesteryl ester transfer protein; HDL-C: high-density lipoprotein cholesterol; TC: total cholesterol; TG: triglyceride; ; versus 0–8 weeks in each group.
